Abstract
The last 10 years have seen significant advances in the understanding of the pathophysiology and treatment of pulmonary arterial hypertension (PAH). This has included new insights into the genetics, cell-signalling pathways and pathological changes seen in the small pulmonary arteries as well as the introduction of new treatments which have improved prognosis. The classification of pulmonary hypertension (PH) has also been changed several times, most recently in 2003. It now divides forms of PH into 5 broad groups according to their pathophysiology and response to treatment. This review focuses primarily on the advances that have been made in the comprehension and treatment of Group 1 (PAH); however reference is also made to other groups within the classification. Pharmacologic treatment now includes calcium-channel blockers, endothelin antagonists, prostanoids, phosphodiesterase type 5 inhibitors, anticoagulants and diuretics. There are 2 recent sets of guidelines directing treatment, one published by the American College of Chest Physicians in 2007 and the most recent published by the National Pulmonary Hypertension Centres of the UK and Ireland in 2008. The recent advances in understanding of the underlying cellular mechanisms have also opened the doorway to new potential therapies such as stem cell transplantation and the targeting of platelet-derived factors and apoptosis.
Keywords: Classification, diagnostics, drug therapy, genetics, hypertension, pulmonary, pathophysiology, practice guidelines
Current Vascular Pharmacology
Title: Pulmonary Arterial Hypertension
Volume: 8 Issue: 3
Author(s): Christiana Burt, Joanna Pepke-Zaba and Florian Falter
Affiliation:
Keywords: Classification, diagnostics, drug therapy, genetics, hypertension, pulmonary, pathophysiology, practice guidelines
Abstract: The last 10 years have seen significant advances in the understanding of the pathophysiology and treatment of pulmonary arterial hypertension (PAH). This has included new insights into the genetics, cell-signalling pathways and pathological changes seen in the small pulmonary arteries as well as the introduction of new treatments which have improved prognosis. The classification of pulmonary hypertension (PH) has also been changed several times, most recently in 2003. It now divides forms of PH into 5 broad groups according to their pathophysiology and response to treatment. This review focuses primarily on the advances that have been made in the comprehension and treatment of Group 1 (PAH); however reference is also made to other groups within the classification. Pharmacologic treatment now includes calcium-channel blockers, endothelin antagonists, prostanoids, phosphodiesterase type 5 inhibitors, anticoagulants and diuretics. There are 2 recent sets of guidelines directing treatment, one published by the American College of Chest Physicians in 2007 and the most recent published by the National Pulmonary Hypertension Centres of the UK and Ireland in 2008. The recent advances in understanding of the underlying cellular mechanisms have also opened the doorway to new potential therapies such as stem cell transplantation and the targeting of platelet-derived factors and apoptosis.
Export Options
About this article
Cite this article as:
Burt Christiana, Pepke-Zaba Joanna and Falter Florian, Pulmonary Arterial Hypertension, Current Vascular Pharmacology 2010; 8 (3) . https://dx.doi.org/10.2174/157016110791112340
DOI https://dx.doi.org/10.2174/157016110791112340 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Early Diagnosis of Alzheimers Disease: Is MCI Too Late?
Current Alzheimer Research Sarcolemmal K<sub>ATP</sub> Channel Modulators and Cardiac Arrhythmias
Current Medicinal Chemistry Validated Spectrodensitometric Method for Simultaneous Estimation of Sofosbuvir, Ribavirin and Saxagliptin in their Pure and Pharmaceutical Dosage Forms
Current Pharmaceutical Analysis Stenting Renal Artery Stenosis: What is the Fuss All About?
Reviews on Recent Clinical Trials The Coronary Circulation in Arterial Hypertension
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Lipoproteins and Diabetic Microvascular Complications
Current Pharmaceutical Design Hybrid Stress Testing by Adenosine Infusion and Exercise Myocardial Perfusion Imaging: A Critical Appraisal
Current Cardiology Reviews Connective Tissue Remodeling: Cross-Talk between Endothelins and Matrix Metalloproteinases
Current Vascular Pharmacology Barriers to Optimising Prescribing and Deprescribing in Older Adults with Dementia: A Narrative Review
Current Clinical Pharmacology Ligand-receptor Engineering and its Application Towards the Complementation of Genetic Disease and Target Identification
Current Topics in Medicinal Chemistry Vitamin D Levels Correlate with Metabolic Syndrome Criteria in Algerian Patients: The Ex-vivo Immunomodulatory Effect of α, 25 Dihydroxyvitamin D3
Endocrine, Metabolic & Immune Disorders - Drug Targets Cardiovascular Health vs Cardiovascular Risk A 2011 Update: Cardiovascular Risk Stratification, the Basis to Reach Therapeutic Goals
Current Hypertension Reviews Metabolic and Cardiovascular Ageing Indices in Relation to Glycated Haemoglobin in Healthy and Diabetic Subjects
Current Aging Science Calcium Sensitizers in Cardiac Surgery: Who, When, How and Why?
Current Vascular Pharmacology A Rationale for Combined Therapy with a Calcium Channel Blocker and a Statin: Evaluation of Basic and Clinical Evidence
Current Drug Targets - Cardiovascular & Hematological Disorders Obesity as a Model of Premature Immunosenescence
Current Immunology Reviews (Discontinued) Liver Enzymes: Potential Cardiovascular Risk Markers?
Current Pharmaceutical Design Gene Expression Suggests Spontaneously Hypertensive Rats May Have Altered Metabolism and Reduced Hypoxic Tolerance
Current Neurovascular Research The Rationale for Comparative Studies of Accelerated Atherosclerosis in Rheumatic Diseases
Current Vascular Pharmacology A Comprehensive Review on Pellets as a Dosage Form in Pharmaceuticals
Current Drug Targets